Evidence map›Paper›PMID 42613562›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Enhanced Transformation Efficiency in Fusobacterium nucleatum by Bypassing Restriction-Modification Systems: A Methylation-Guided Protocol.

Ling Liu, Yu Zhang, Xue Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ling Liu *Department of Laboratory Medicine, Key Laboratory of Precision Medicine for Viral Diseases, Guangxi Health Commission Key Laboratory of Clinical Biotechnology, Liuzhou People's Hospital, Liu Zhou, China.
Yu Zhang *Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pathogen Biology, International Cancer Center, Shenzhen University Medical School, Shenzhen, China.
Xue LiuGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pathogen Biology, International Cancer Center, Shenzhen University Medical School, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The genetic intractability of Fusobacterium nucleatum has slowed progress in defining mechanisms of fusobacterial pathogenesis. Transformation is inefficient, and broadly applicable genetic tools are still limited. A major obstacle is the presence of endogenous restriction-modification (RM) systems that cleave incoming DNA lacking appropriate methylation. This chapter presents a concise, reproducible protocol to increase transformation efficiency in F. nucleatum by systematically bypassing RM barriers. The workflow combines methylome mapping by single-molecule real-time (SMRT) sequencing, expression of cognate methyltransferases (MTases) in an intermediary Escherichia coli host to pre-methylate shuttle plasmids, and optimized electroporation with careful anaerobic handling and selective recovery. Using F. nucleatum ATCC 25586 as an example, the method yields a marked improvement in transformation efficiency, and the same logic can be adapted to additional F. nucleatum isolates once their methylation context is defined.

Indexed as

DNA MethylationDNA Restriction-Modification EnzymesFusobacterium nucleatumTransformation, BacterialDNA, BacterialElectroporationEscherichia coliMethyltransferasesPlasmidsDNA, BacterialDNA Restriction-Modification EnzymesMethyltransferasesFusobacterium nucleatumMethylationRestriction-modificationTransformation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.